Clinical trials recruiting for Ocular Hypertension

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
  NCT07325240 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
  NCT06267274 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma
  NCT07119580 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
  NCT05401357 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
  NCT07217678 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• DSLT for Reducing Medication in Glaucoma
  NCT07390890 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells
  NCT04957329 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
  NCT07335211 · Phase: Phase 3 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
  NCT07218783 · Phase: Phase 3 · Ages: 22 Years and older · Sex: All (male and female) · 1 location
• Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
  NCT07218796 · Phase: Phase 3 · Ages: 22 Years and older · Sex: All (male and female) · 1 location
• Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
  NCT07588152 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
  NCT06629649 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Inflammatory Biomarkers in Ocular Surface in Primary Open Angle Glaucoma or Ocular Hypertension Under Topical Prostaglandins
  NCT05039684 · Phase: Not specified · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Intraocular Pressure Measured by a Novel Sensing Contact Lens Versus Tonometry
  NCT04024293 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Investigation of Neurovascular Coupling in Glaucoma Patients and Healthy Subjects
  NCT03870230 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) Shunt
  NCT06691555 · Phase: Not specified · Ages: 40 Years to 90 Years · Sex: All (male and female) · 1 location
• Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
  NCT04401982 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
  NCT05844384 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery
  NCT07036510 · Phase: Phase 1, Phase 2 · Ages: 40 Years and older · Sex: All (male and female) · 1 location
• [KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
  NCT07662759 · Phase: Phase 3 · Ages: 19 Years and older · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Ocular Hypertension often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Ocular Hypertension trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.